AUA 2017: Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Subgroup Analysis from S-TRAC Trial
They were included in the study if they had completely resected stage T3 and higher clear cell renal cell carcinomas and were randomized to sunitnib 50 mg on a 4-week-on, 2-week-off schedule versus placebo (N Engl J Med. 2016;375:2246). The primary analysis demonstrated improved disease-free survival (DFS) for the sunitnib arm relative to placebo (hazard ratio 0.76, 95% confidence interval 0.59-0.98). There was no difference in recurrence patterns between the two arms.
Dr. Pantuck offered data specifically on patients with high Fuhrman grade (3 or higher) tumors and T3 or greater disease. Again, an improvement in DFS was observed for individuals in the sunitinib arm (6.2 years vs. 4.0 years, P < .05). The overall survival endpoint for this subgroup has not yet been met. He concluded that subgroup analyses are consistent with the primary analysis confirming a benefit in DFS favoring adjuvant sunitinib. With time, differences in overall survival may become more apparent.
Presented By: Allan Pantuck, MD, UCLA, Los Angeles, CA
Written By: Benjamin T. Ristau, MD, Fox Chase Cancer Center, Philadelphia, PA
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA